Search PubMed⌕ Search

Biomedical subjects

M D Lockshin

Publications and source records attributed to M D Lockshin.

155 records · Page 9Linked to original sources
PubMedDate not supplied

Immunologic observations on 9 sets of twins either concordant or discordant for SLE.

The influence of genetic and nongenetic factors on abnormalities of the immune response in systemic lupus erythematosus (SLE) was studied in 9 sets of twins in which one or both twins had SLE. Particular emphasis was placed on contrasting the results between the sibs of 3 monozygotic pairs discordant for clinical SLE. Depression of cell-mediated immunity, determined by lymphocyte blastogenic response to mitogens, was associated with the clinical expression of illness. In contrast, autoreactive antilymphocyte antibodies and lymphocyte tubuloreticular structures were found in both clinically affected and unaffected subjects and were more prominently associated with the presence of other serologic abnormalities. No evidence of antigens or cell surfaces determinants unique to affected sibs was encountered.

Adult↗
PubMedDate not supplied

Overview of lupus pregnancies.

Pregnancy in patients with systemic lupus erythematosus (SLE) requires consideration of 5 major issues: (1) What is the risk to the mother? (2) What is the risk to the fetus? (3) What is the effect and treatment of antiphospholipid antibody? (4) What is the risk of neonatal lupus? (5) Stability of the family unit, particularly in the events of maternal disability or death, should be discussed by all parties when a pregnancy is planned. Consistency of measurement criteria, standardized treatment protocols, and long-term follow-ups are needed in the future.

Abortion, Spontaneous↗
PubMedDate not supplied

A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis.

OBJECTIVE: To survey the effectiveness of etanercept in the treatment of severe, resistant psoriatic arthritis. METHODS: Ten patients coming from the clinical practice of 5 different rheumatologists and already using etanercept (25 mg subcutaneously twice weekly) were formally assessed at 3 and 12 months after etanercept use. RESULTS: All patients had improvement in their arthritis. Five of the 10 patients had no arthritis, 4 required only etanercept for disease control at 3 months. At 12 months, 8 of 10 patients were still on etanercept with continued good response. One patient had to discontinue etanercept due to osteomyelitis, and one due to increased disease activity. Of 4 patients with active skin disease, 3 had complete clearing. There were no side effects related to etanercept in this small, heterogeneously collected group of patients. CONCLUSIONS: This preliminary and rather favorable experience with etanercept suggests that properly controlled trials of this agent in psoriatic arthritis are needed.

Adult↗
PubMedDate not supplied

Auto-immunological basis of disk degeneration.

Ninety-four subjects were divided into 5 groups according to symptoms and radiologic findings to devise a test for immunoglobin levels and lymphocyte microstimulation. Cellular immunity to disk antigens can be demonstrated in disk degeneration which may be primary or secondary. The serum level of IgM, irrespective of the age of the individual was significantly higher in patients with backache than asymptomatic patients.

Adolescent↗
PubMedDate not supplied

Alternative complement pathway in hypocomplementemic/normal C1s-C1 inhibitor complex patients with SLE.

To test whether alternative complement pathway activation explains normal C1s-C1 inhibitor complex in hypocomplementemic (low CH50cl) patients with systemic lupus erythematosus, we examined alternative pathway hemolytic complement (CH50alt) factor B, and Ba fragment in hypocomplementemic sera with normal and with elevated C1s-C1 inhibitor complex. Sera with and without high C1s-C1 inhibitor complex were similar in CH50cl, C3, and C4. There was little evidence for important alternative complement pathway activation in either group, but patients with classical pathway activation (elevated C1s-C1 inhibitor complex) had slightly lower CH50alt and slightly higher factor B and Ba compared to patients with normal C1s-C1 inhibitor complex. Pregnant patients did not differ from non-pregnant patients. Alternative complement pathway activation does not account for hypocomplementemia in this group of patients.

Complement Activation↗
PubMedDate not supplied

Pregnancy in systemic lupus erythematosus.

Experience with more than 150 pregnancies of women with systemic lupus erythematosus demonstrates that: many conventional measures of lupus activity, including complement, platelet count and urinary protein, are invalid during pregnancy; pregnancy does not cause lupus exacerbation; anti-phospholipid antibody is common and is closely associated with fetal loss, but is not the sole determinant factor of fetal loss; specific characteristics of anti-phospholipid antibody do not identify which antibody-positive women will have poor fetal outcome; prednisone therapy does not improve fetal prognosis; and neonatal lupus, diagnosed by rash and thrombocytopenia, is common but congenital heart block is rare.

Autoantibodies↗
PubMedDate not supplied

Posterior compartment syndrome resulting from a dissecting popliteal cyst. Case report.

Calf swelling, associated with an intra-articular effusion of the knee, should be considered a dissecting popliteal cyst until proven otherwise. The posterior compartment syndrome caused by an increase in pressure within the deep posterior compartment of the leg is usually secondary to trauma. This case history of a dissecting popliteal cyst reports another unusual cause of the posterior compartment syndrome. Popliteal cysts, especially dissecting ones, are typical of connective tissue diseases, and are not limited to rheumatoid arthritis.

Bone Cysts↗